Companies Dominating the Small Interfering RNA Landscape
- GE
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Thermo Scientific
- Arbutus Biopharma
- Sanofi Genzyme
- Sylentis
- Arrowhead Research
- Genecon Biotechnologies
- Silent Therapeutics
- Horizon Discovery
- OPKO Health
- Agios Pharmaceuticals, Inc.
- Novartis
Browse Key Market Insights with Data Illustration:
In the News
- Agios Pharmaceuticals, Inc. partnered with Alnylam Pharmaceuticals, Inc. announced to develop and commercialize Alnylam's innovative preclinical siRNA targeting TMPRSS6, for patients with polycythemia vera (PV), a rare hematologic condition. Furthermore, the company aims to provide a simple, disease-modifying therapy option that targets the underlying pathophysiology of PV and to provide a breakthrough therapy option for this patient community with significant unmet needs.
- Novartis received approval from the US Food and Drug Administration (FDA) for Leqvio (inclisiran) a small interfering RNA (siRNA) therapy a new strategy to lower low-density lipoprotein cholesterol also known as bad cholesterol in the bloodstream by increasing the liver's natural ability to suppress the creation of a protein that contributes to high circulating cholesterol levels to assist those who have difficulty sticking to self-administered medications with higher dose frequency.
